Medicus Pharma signs non-binding MoU with HelixNano for thermostable mRNA vaccine development

Medicus Pharma Ltd.

Non-binding MoU to combine Medicus' MNA delivery platform with HelixNano's mRNA platform for thermostable infectious disease vaccines.
Parties aim to form a joint venture for co-development and commercialization of thermostable mRNA-based vaccines.
Plan a Phase 1 bridging study comparing IM injection vs. intradermal MNA delivery of HelixNano's vaccine candidate HN-0001.
Preliminary activities include a Sponsored Research Agreement with University of Pittsburgh (Dr. Lou Falo), supply of HN-0001, and loading into Medicus' MNAs.
MoU is non-binding; no obligation to proceed with joint venture until definitive agreements are executed.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.